Pfizer to Sell Stake in Pandemic Vaccine Partner BioNTech (1)

Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations.

The US drugmaker is offering about 4.55 million American depositary receipts via an overnight block trade marketed between $108 to $111.70 per share, according to people familiar with the matter. At the high end of the price range, the stake sale would be worth about $508 million for Pfizer.

Pfizer declined to comment, while BioNTech didn’t immediately respond to a request for comment. US-listed shares of BioNTech fell 3.6% in premarket trading, while ...